Want to see TOVX full AI Analyst Report?
Top Page
Theriva Biologics
(TOVX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.25
▲(3.75% Upside)
Action:Reiterated
Date:08/18/26
Overall score is held down primarily by weak financial performance (ongoing large losses and cash burn with a shrinking equity cushion). Technicals are broadly neutral-to-soft with limited momentum, and valuation is constrained by negative earnings and no dividend support. Corporate events add some upside via clinical trial progress but are partially offset by dilution/financing overhang.
Positive Factors
VIRAGE2 clinical progression
Dosing the first patient advances VCN-01 into a focused proof-of-concept study and creates a defined path toward regimen optimization. If the trial confirms safety and pharmacodynamic activity, it could strengthen the case for a pivotal Phase 3 program in pancreatic cancer.
Negative Factors
Persistent cash consumption
Ongoing operating and free-cash-flow deficits show that development activities require substantial external funding rather than being supported by internally generated cash. Continued burn can restrict strategic flexibility and increase dependence on future financing while clinical milestones remain uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
VIRAGE2 clinical progression
Dosing the first patient advances VCN-01 into a focused proof-of-concept study and creates a defined path toward regimen optimization. If the trial confirms safety and pharmacodynamic activity, it could strengthen the case for a pivotal Phase 3 program in pancreatic cancer.
Read all positive factors
Theriva Biologics (TOVX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.61M
Dividend YieldN/A
Average Volume (3M)556.11K
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue GrowthN/A
EPS Growth94.38%
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.67
Shares Outstanding45,892,670
10 Day Avg. Volume588,155
30 Day Avg. Volume556,110
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.00Price Target Upside316.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$29.37M
Theriva Biologics Business Overview & Revenue Model
Company Description
Theriva Biologics Inc. is a clinical-stage biotechnology firm dedicated to developing novel treatments for conditions with significant unmet medical needs. The company's pipeline features several promising candidates, including SYN-004, which is e...
How the Company Makes Money
Theriva Biologics does not have publicly established, recurring product revenue from marketed therapies; as a clinical-stage company, its activities are primarily R&D-driven, so ongoing operations have typically been funded through external financ...
Theriva Biologics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
45
Neutral
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 276.00K | -108.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -11.54M | -23.63M | -19.29M | -21.96M | -19.20M | -14.18M |
| Net Income | -11.62M | -25.25M | -25.65M | -18.35M | -19.68M | -14.27M |
Balance Sheet | ||||||
| Total Assets | 34.86M | 38.24M | 35.35M | 55.22M | 71.86M | 70.36M |
| Cash, Cash Equivalents and Short-Term Investments | 11.34M | 13.06M | 11.61M | 23.18M | 41.79M | 67.33M |
| Total Debt | 3.55M | 2.63M | 1.56M | 2.15M | 1.68M | 1.53M |
| Total Liabilities | 22.67M | 22.86M | 16.29M | 15.52M | 17.30M | 4.96M |
| Stockholders Equity | 12.19M | 15.38M | 19.07M | 39.70M | 54.56M | 65.41M |
Cash Flow | ||||||
| Free Cash Flow | -12.38M | -16.70M | -16.94M | -19.20M | -19.20M | -12.90M |
| Operating Cash Flow | -12.35M | -16.67M | -16.94M | -19.00M | -19.08M | -12.89M |
| Investing Cash Flow | -22.00K | -35.00K | -1.00K | -202.00K | -4.40M | -14.00K |
| Financing Cash Flow | 14.46M | 18.19M | 5.50M | 625.00K | -1.93M | 74.00M |
Theriva Biologics Technical Analysis
Positive
0.24
Price Trends
0.23
Positive
0.27
Negative
0.24
Positive
Market Momentum
<0.01
Negative
58.42
Neutral
58.49
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TOVX, the sentiment is Positive. The current price of 0.24 is above the 20-day moving average (MA) of 0.24, above the 50-day MA of 0.23, and above the 200-day MA of 0.24, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 58.42 is Neutral, neither overbought nor oversold. The STOCH value of 58.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TOVX.
Theriva Biologics Risk Analysis
Theriva Biologics disclosed 62 risk factors in its most recent earnings report. Theriva Biologics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Theriva Biologics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $11.61M | -0.38 | -93.49% | ― | ― | 94.38% | |
46 Neutral | $20.08M | >-0.01 | -147.45% | ― | ― | ― | |
46 Neutral | $11.83M | -0.64 | -91.18% | ― | ― | 81.87% | |
43 Neutral | $14.87M | -1.01 | -113.79% | 0.03% | -90.65% | 26.48% | |
42 Neutral | $8.18M | -0.95 | -237.91% | ― | ― | 23.05% | |
42 Neutral | $10.36M | -0.19 | -1539.97% | ― | ― | 80.28% |
* Healthcare Sector Average
TOVX
Theriva Biologics
0.25
-0.13
-34.63%
LSTA
Lisata Therapeutics
1.65
-0.53
-24.31%
AKTX
Akari Therapeutics
11.47
-22.53
-66.26%
XCUR
Exicure
1.25
-3.05
-70.93%
INAB
IN8bio
1.20
-0.96
-44.44%
SNTI
Senti Biosciences
0.33
-0.99
-74.85%
Theriva Biologics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Theriva Begins VIRAGE2 Trial in Metastatic Pancreatic Cancer
Positive
Aug 6, 2026
On August 6, 2026, Theriva Biologics announced it had dosed the first patient in its VIRAGE2 Phase 2a proof-of-concept trial, which is testing more frequent dosing of VCN-01 alongside standard gemcitabine/nab-paclitaxel chemotherapy in first-line ...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Theriva Biologics Expands Stock Incentive and Governance Plans
Positive
Aug 4, 2026
On August 3, 2026, Theriva Biologics, Inc. held its 2026 Annual Meeting of Stockholders, at which shareholders approved Amendment No. 4 to the 2020 Stock Incentive Plan, raising the pool of shares available for equity awards from 4,500,000 to 6,50...
Business Operations and StrategyProduct-Related Announcements
Theriva Biologics launches VIRAGE2 metastatic pancreatic trial
Positive
Jul 7, 2026
On July 7, 2026, Theriva Biologics announced that Spain’s medicines regulator AEMPS authorized the start of VIRAGE2, a Phase IIa, single-arm, open-label proof-of-concept trial testing more frequent dosing of VCN-01 with gemcitabine/nab-pacli...
Business Operations and Strategy
Theriva Biologics highlights promising VCN-01 Phase 1 results
Positive
Jun 11, 2026
On June 11, 2026, Theriva Biologics announced that results from a Phase 1 trial of its oncolytic adenovirus VCN-01 combined with the checkpoint inhibitor durvalumab in 20 heavily pretreated metastatic head and neck squamous cell carcinoma patients...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.